Metabolic Dysfunction‐Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda
Authors:
- Mohamed El‐KassasMEMohamed El‐Kassas
- Marcela Villota‐RivasMVMarcela Villota‐Rivas
- Khalid A. AlswatKAKhalid A. Alswat
- Khalid M. AlNaamaniKAKhalid M. AlNaamani
- Yusuf YilmazYYYusuf Yilmaz
- Asma LabidiALAsma Labidi
- Faisal M. SanaiFSFaisal M. Sanai
- Abeer AwadAAAbeer Awad
- Maisam W. I. AkroushMAMaisam W. I. Akroush
- Saleh A. AlqahtaniSASaleh A. Alqahtani
- Mohamed ElbadryMEMohamed Elbadry
- Nermeen AbdeenNANermeen Abdeen
- 23 May 2025
- journal article
- Published by Wiley in Liver International
- Vol. 45 (6) , e70108
Abstract
Background & Aims: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus‐driven research and action agenda to address MASLD within the MENA region.Methods: Following a global MASLD research and action agenda setting study, over two Delphi rounds (Rs), MENA region experts (R1 n = 112, R2 n = 104) indicated their level of agreement with and provided feedback on MASLD research and action priorities via Qualtrics XM. In R2, panellists also ranked the priorities, which were categorised across six domains: (1) the human and economic burden, (2) defining and implementing care models, (3) disease management, (4) education and awareness, (5) patient and community perspectives, and (6) leadership and policies for the MASLD public health agenda.Results: The consensus‐built MASLD research and action priority agenda for the MENA region comprises 52 priorities. Combined agreement (i.e., ‘agree’ + ‘somewhat agree’) increased from 97.6% and 98.1% in R1 to 98.2% and 98.5% in R2 with the research (n = 30) and action (n = 22) priorities, respectively. The highest ranked research priorities included developing regional MASLD databases and validating non‐invasive diagnostic tools. The highest ranked action priorities included taking steps to enhance the adoption of lifestyle interventions among people living with MASLD and improving disease knowledge among healthcare providers.Conclusions: This region‐specific agenda can help to guide research and optimise clinical practice, thereby improving the understanding, prevention, and management of MASLD, enhancing health outcomes and reducing its burden within the MENA region.Keywords
Funding Information
- Instituto de Salud Global de Barcelona
This publication has 26 references indexed in Scilit:
- Research Priorities for Precision Medicine in NAFLDClinics in Liver Disease, 2023
- Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East RegionClinics in Liver Disease, 2023
- A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2022
- Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care SystemClinical Gastroenterology and Hepatology, 2020
- Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th editionDiabetes Research and Clinical Practice, 2019
- Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling StudyHepatology, 2019
- Patient‐Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value PropositionHepatology, 2018
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Considerations for an Obesity Policy Research AgendaAmerican Journal of Preventive Medicine, 2009